Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
83 hedge funds and large institutions have $111M invested in Odonate Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 35 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 23
12% less funds holding
Funds holding: 94 → 83 (-11)
18% less call options, than puts
Call options by funds: $906K | Put options by funds: $1.1M
31% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 35
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
85% less capital invested
Capital invested by funds: $721M → $111M (-$611M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$25.3M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$11.1M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$9.45M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$7.49M |
| 5 |
Two Sigma Investments
New York
|
+$5.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$72.4M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$52.3M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$23.3M |
| 4 |
RI
RTW Investments
New York
|
-$19.2M |
| 5 |
Morgan Stanley
New York
|
-$8.18M |
ODT Hedge Fund Activity: Q1 2021 in Review
83 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q1 2021, worth a combined $111M — down 85% from $721M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of ODT and 24 opened new positions — a net loss of 11 holders — while 23 trimmed existing stakes and 25 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $25.3M. The largest seller was Wellington Management Group, exiting entirely with an estimated $72.4M sold.
- 83 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q1 2021, down from 94 in Q4 2020.
- Funds reported $111M of Odonate Therapeutics, Inc. Common Stock stock for Q1 2021, down 85% quarter-over-quarter.
- 24 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q1 2021 and 35 closed out, a net change of -11 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q1 2021 was Ikarian Capital, an estimated $25.3M added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q1 2021 was Wellington Management Group, an estimated $72.4M sold.
Based on aggregated 13F filings for Q1 2021.